Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 886 to 900 of 1561 results for do not do recommendations

  1. Synergo for non-muscle-invasive bladder cancer (HTG601)

    Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer.

    HealthTech guidance
    Published
    30 November 2021
    View recommendations

    Sections for HTG601

  2. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    Recommendation ID NG89/1 Question Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of

    Research recommendation
    Published
    15 November 2018

  3. Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (TA1101)

    Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.

    Technology appraisal guidance
    Published
    8 October 2025
    View recommendations

    Sections for TA1101

  4. Our charter

    An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.

  5. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    Recommendation ID NG191/18 Question What is the effectiveness of awake body positioning in improving outcomes for people in hospital with

    Research recommendation
    Published
    9 March 2022

  6. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    23 October 2007
    View recommendations

    Sections for TA129

  7. Privacy notice

    How we collect and use your personal information, and your rights under data protection legislation.

  8. What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?

    Recommendation ID NG151/1 Question What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy

    Research recommendation
    Published
    10 February 2020

  9. Ruxolitinib for treating polycythaemia vera (TA921)

    Evidence-based recommendations on ruxolitinib (Jakavi) for polycythaemia vera in adults.

    Technology appraisal guidance
    Published
    18 October 2023
    View recommendations

    Sections for TA921

  10. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (HTG659)

    Evidence-based recommendations on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer. This involves pushing the rectum slightly away from the prostate by inserting a balloon or injecting a gel (spacer) between them.

    HealthTech guidance
    Published
    7 February 2023
    View recommendations

    Sections for HTG659

  11. The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)

    Evidence-based recommendations on the PLASMA system for transurethral resection and haemostasis of the prostate.

    HealthTech guidance
    Published
    6 January 2021
    View recommendations

    Sections for HTG563

  12. The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia shows there are serious but well-recognised complications. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should not be used unless  special arrangements   are in place for clinical governance, consent, and audit or research.

    Recommendation ID IPG654/1 Question The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh

    Research recommendation
    Published
    15 November 2019

  13. Education and training programmes: self-management:- What is the effectiveness and cost effectiveness of education programmes to improve information and advice and to support self-management of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing older with learning disabilities, and their family members and carers?

    Recommendation ID NG96/3 Question Education and training programmes: self-management:- What is the effectiveness and cost effectiveness

    Research recommendation
    Published
    29 November 2018

  14. The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI raises no major safety concerns other than those associated with the TAVI procedure. However, the evidence on efficacy for preventing TAVI-related stroke is inconclusive. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG650/1 Question The evidence on percutaneous insertion of a cerebral protection device to prevent cerebral embolism

    Research recommendation
    Published
    15 November 2019

  15. Subscribe to our GP reference panel

    Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.